• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Anika misses revenue, earnings estimates in Q3

October 26, 2017 By Sarah Faulkner

Anika TherapeuticsAnika Therapeutics (NSDQ:ANIK) missed expectations on Wall Street with its third quarter results, the company reported yesterday after the market closed.

The Bedford, Mass.-based company posted profits of $14.6 million, or 47¢ per share, on sales of $27.2 million for the 3 months ended Sept. 30, for a bottom-line loss of -0.3% on sales growth of 5.4% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were 46¢, a penny behind consensus on The Street, where analysts were looking for sales of $28.9 million.

“Anika made significant progress on multiple fronts executing its long-term growth strategy, highlighted by the early completion of enrollment in the Cingal Phase III trial, regulatory clearances for the expansion of Monovisc into India, Australia, and Taiwan, pipeline advancements and the bolstering of our executive and commercial leadership team,” CEO Charles Sherwood said in prepared remarks.

“Monovisc continued to gain worldwide market share in the third quarter as physicians continue to migrate towards single-injection solutions, resulting in Monovisc revenue growth of 50% year-over-year for the quarter. Additionally, we advanced our regenerative medicine pipeline with the submission of a 510(k) application to the U.S. Food and Drug Administration for our injectable HA-based bone repair treatment, a promising new opportunity gaining attention in the orthopedic space.”

Earlier this month, the company’s single injection viscosupplement, Monovisc, for the treatment of pain associated with osteoarthritis of the synovial joints was approved for use in Australia.

This latest regulatory win means that Monovisc is commercially available in more than twenty countries, including the U.S. and Canada. Anika said it plans to move into additional international markets next year with its therapy for hip and knee pain.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Orthopedics, Wall Street Beat Tagged With: Anika Therapeutics Inc.

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS